Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 110-115

  Liu, Li ^a   Yuan, Peng ^b   Wu, Chen ^b   Zhang, Xiaomin ^a   Wang, Feng ^a   Guo, Huan ^a   Zhong, Rong ^a   Xu, Yihua ^a   Wu, Jing ^a   Yu, Dianke ^b   Wu, Tangchun ^a   Zhang, Xuemei ^c   Nie, Shaofa ^a   Miao, Xiaoping ^a   Lin, Dongxin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CANCER HOSPITAL   (China)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Non small cell lung cancer; Platinum; Polymorphisms; Survival; XPD; XRCC1

Indexed keywords

ANTIINFECTIVE AGENT; PLATINUM DERIVATIVE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 79957745242     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.11.004     Document Type: Article

References (47)

1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
2. Schneider J., Classen V., Helmig S. XRCC1 polymorphism and lung cancer risk. Expert Rev Mol Diagn 2008, 8:761-780.
3. Yu D., Zhang X., Liu J., Yuan P., Tan W., Guo Y., et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008, 14:2878-2886.
4. Cortinovis D., Bidoli P., Zilembo N., Fusi A., Bajetta E. Oxiplatin doublets in non-small cell lung cancer: a literature review. Lung Cancer 2008, 60:325-331.
5. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000, 59:9-17.
6. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J Clin 2005, 55:74-108.
7. Danesi R., de Braud F., Fogli S., de Pas T.M., Di Paolo A., Curigliano G., et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003, 55:57-103.
8. Rosell R., Lord R.V., Taron M., Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38:217-227.
9. Wei Q., Frazier M.L., Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 2000, 92:440-441.
10. Vineis P., Manuguerra M., Kavvoura F.K., Guarrera S., Allione A., Rosa F., et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 2009, 101:24-36.
11. Wolfe K.J., Wickliffe J.K., Hill C.E., Paolini M., Ammenheuser M.M., Abdel-Rahman S.Z. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 2007, 17:897-905.
12. Shen M.R., Jones I.M., Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998, 58:604-608.
13. Hao B., Wang H., Zhou K., Li Y., Chen X., Zhou G., et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004, 64:4378-4384.
14. Hao B., Miao X., Li Y., Zhang X., Sun T., Liang G., et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 2006, 25:3613-3620.
15. Liang G., Xing D., Miao X., Tan W., Yu C., Lu W., et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003, 105:669-673.
16. Blin N., Stafford D.W. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acid Res 1976, 3:2303-2308.
17. Yuan P., Miao X.P., Zhang X.M., Wang Z.H., Tan W., Sun Y., et al. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Chin J Oncol 2006, 28:196-199.
18. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004, 22:2594-2601.
19. van de Vaart P.J., Belderbos J., de Jong D., Sneeuw K.C., Majoor D., Bartelink H., et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000, 89:160-166.
20. Kennedy R.D., D'Andrea A.D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006, 24:3799-3808.
21. Reed E. Platinum-DNA adducts nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998, 24.
22. de Boer J., Hoeijmakers J.H. Nucleotide excision repair and human syndromes. Carcinogenesis 2000, 21:453-460.
23. Liu H., Rudolf J., Johnson K.A., McMahon S.A., Oke M., Carter L., et al. Structure of the DNA repair helicase XPD. Cell 2008, 133:801-812.
24. Lehmann A.R. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev 2001, 15:15-23.
25. Benhamou S., Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005, 161:1-14.
26. Long X.D., Ma Y., Zhou Y.F., Yao J.G., Ban F.Z., Huang Y.Z., et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer 2009, 9:400.
27. Lopez-Cima M.F., Gonzalez-Arriaga P., Garcia-Castro L., Pascual T., Marron M.G., Puente X.S., et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer 2007, 7:162.
28. Liu G., Zhou W., Yeap B.Y., Su L., Wain J.C., Poneros J.M., et al. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis 2007, 28:1254-1258.
29. Jiao L., Hassan M.M., Bondy M.L., Abbruzzese J.L., Evans D.B., Li D. The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett 2007, 245:61-68.
30. Popanda O., Schattenberg T., Phong C.T., Butkiewicz D., Risch A., Edler L., et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004, 25:2433-2441.
31. Au W.W., Salama S.A., Sierra-Torres C.H. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003, 111:1843-1850.
32. Baute J., Depicker A. Base excision repair and its role in maintaining genome stability. Crit Rev Biochem Mol Biol 2008, 43:239-276.
33. Kiyohara C., Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007, 4:59-71.
34. Hu Z., Ma H., Lu D., Zhou J., Chen Y., Xu L., et al. A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics 2005, 15:457-463.
35. Syamala V.S., Syamala V., Sreedharan H., Raveendran P.B., Kuttan R., Ankathil R. Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report. Pathol Oncol Res 2009, 15:389-397.
36. Kalikaki A., Kanaki M., Vassalou H., Souglakos J., Voutsina A., Georgoulias V., et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:118-123.
37. Gandara D.R., Kawaguchi T., Crowley J., Moon J., Furuse K., Kawahara M., et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009, 27:3540-3546.
38. Chew H.K., Doroshow J.H., Frankel P., Margolin K.A., Somlo G., Lenz H.J., et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009, 27:2163-2169.
39. Bradbury P.A., Kulke M.H., Heist R.S., Zhou W., Ma C., Xu W., et al. Cisplatin pharmacogenetics. DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009, 19:613-625.
40. Ruzzo A., Graziano F., Loupakis F., Santini D., Catalano V., Bisonni R., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008, 8:278-288.
41. Pare L., Marcuello E., Altes A., del Rio E., Sedano L., Salazar J., et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008, 99:1050-1055.
42. Hsieh W.C., Cheng Y.W., Lin C.J., Chou M.C., Chen C.Y., Lee H. Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer. Jpn J Clin Oncol 2009, 39:81-85.
43. Giachino D.F., Ghio P., Regazzoni S., Mandrile G., Novello S., Selvaggi G., et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007, 13:2876-2881.
44. Yin Z., Zhou B., He Q., Li M., Guan P., Li X., et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 2009, 9:439.
45. Huang R.S., Ratain M.J. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009, 59:42-55.
46. Manuguerra M., Matullo G., Veglia F., Autrup H., Dunning A.M., Garte S., et al. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis 2007, 28:414-422.
47. Wu X., Hildebrandt M.A., Chang D.W. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev 2009, 28:269-280.